Aisthesis Medical Secures $1.2M for AI Sepsis Prediction Platform

Aisthesis Medical has announced the successful closing of a $1.2 million pre-seed funding round. The funding, led by Twin Path Ventures with participation from TECS Capital, will be used to accelerate the development and regulatory clearance of VIOSync SPI, an AI-powered clinical decision support platform.

VIOSync SPI is designed to predict the onset of sepsis within the next 48 hours by securely ingesting multimodal patient data from hospital systems. This platform aims to provide clinicians with actionable insights to intervene earlier and potentially save lives. The investment will support the advancement of CE MDR submission for VIOSync SPI and expand clinical validation studies across leading hospitals in the UK and EU.

The funding will also enable Aisthesis Medical to strengthen its team and prepare for NHS and international pilot deployments, furthering its mission to empower clinicians with trusted AI tools for preventing life-threatening conditions.